https://africanjournalofbiomedicalresearch.com/index.php/AJBR
Afr. J. Biomed. Res. Vol. 28(3s) (April 2025); 01-14
Research Article

Diagnosis Of Candida Infection in Blood: Species Identification and Molecular Approaches

Shivangi Tripathi[1,2], Gopa Banerjee[1*], Renu Kumari[1], Aisha Kamal[2], Balwant Singh[3], Vijay Laxmi[1]

[1]Department of Microbiology, King George Medical University, Lucknow-206003, Uttar Pradesh, India.
[2]Division of Mycology, Department of Bioscience, Integral University, Lucknow-226026, Uttar Pradesh, India.
[3]Division of Mycology, Department of Botany, Dr. Ram Manohar Lohia Avadh University Ayodhya-224001, Uttar Pradesh, India.

***Corresponding Author:** Prof. Gopa Banerjee
*Department of Microbiology, King George's Medical University, Lucknow, INDIA. Pin Code: 226003
E-mail – gopa.banerjee31@rediffmail.com, Mobile: +91 7607363833

ABSTRACT
Candida species are opportunistic fungal pathogens that cause bloodstream infections, primarily in immunocompromised patients. The early and accurate determination of candidemia is considered important for effective treatment and improved patient outcomes. The traditional methods for diagnosing candidemia, including blood cultures and phenotypic identification, are time-consuming and have limitations regarding sensitivity and species differentiation. Over the past years, molecular techniques have transformed the approach toward diagnosing *Candida* infections by providing better sensitivity, specificity, and ability to differentiate between species. Polymerase chain reaction, real-time PCR, DNA sequencing, and metagenomic analysis are among these newer techniques, giving more precise results in less time and therefore appropriate intervention in due course. The current review summarises the molecular approaches for *Candida* species identification from blood with respect to advantages, challenges, and clinical utility. It also delves into the monitoring of antifungal resistance, improving patient management, and personalizing therapy with these methods. Future advancements in genomic technologies may further improve the accuracy and speed of *Candida* infection diagnostics.

Keywords: *Candida, Candidemia, Molecular Diagnostics, PCR, Species Identification.*

***Author of Correspondence E mail:** gopa.banerjee31@rediffmail.com*

Received:25/03/2025 *Acceptance:03/04/2025*

DOI: https://doi.org/10.53555/AJBR.v28i3S.7294

ABBREVIATION

AIDS	Acquired Immuno-Deficiency Syndrome
CRISPR	Clustered Regularly Interspaced Short Palindromic Repeats
DNA	Deoxyribonucleic Acid
EIA	Enzyme Immunoassay

ERG11	Ergosterol biosynthesis enzyme-11
FCY2	Flucytosine-Cytosine Permease-2 (Gene)
FKS Gene	Fungal Beta-(1,3)-Glucan Synthase gene
FUR1	Flucytosine-Uracil Phosphoribosyltransferase-1 (Gene)
HIV	Human Immuno-Deficiency Virus
HTS	High-Throughput Screening
ICU	Intensive Care Units
ITS	Internal Transcribed Spacer
LAMP	Loop-Mediated Isothermal Amplification
LSU rRNA	Large Subunit Ribosomal RNA
MALDI-TOF	Matrix-assisted laser desorption/ionization-Time of Flight
MLST	Multi-locus Sequence Typing
NAC	N-Acetylcysteine
NGS	Next-Generation Sequencing
PCR	Polymerase Chain Reaction
POC	Point-of-Care
qPCR	Quantitative PCR
RNA	Ribonucleic Acid
RPA	Recombinase Polymerase Amplification
RT-PCR	Real-time PCR
WGS	Whole Genome Sequencing

1. INTRODUCTION

Candida infections, especially bloodstream infections, are an important cause of morbidity and mortality in immunocompromised patients, such as those who receive chemotherapy, organ transplants, or those who have diabetes or HIV/AIDS (Zhao et al., 2023). The infections are now being increasingly considered as a significant health concern in intensive care units (ICUs), where candidemia has seen a dramatic increase over the years (López et al., 2021). The timely and accurate diagnosis of Candida infections in blood is important for the effective management of these cases, as delays in diagnosis can lead to poor clinical outcomes, including increased mortality and prolonged hospitalization (Sharma et al., 2022).

Traditional diagnostic methods that include blood cultures are still quite common for identifying Candida species, but are time-consuming, and infections tend to go unnoticed in a timely manner, especially when the burden of fungi is very low (Khan et al., 2017). Moreover, conventional methods such as microscopy and biochemical testing may lack the precision necessary for the accurate identification of a species, which forms the basis for the selection of the appropriate antifungal agent (Brown et al., 2019). Candida species exhibit significant genetic diversity, and differences in their pathogenicity and antifungal susceptibility necessitate accurate species-level identification to guide therapeutic decisions (Kullberg & Arendrup, 2015).

Advances in molecular diagnostics have now made the identification and detection of Candida species in blood samples faster, more sensitive, and specific. The techniques, based on polymerase chain reaction (PCR), have further become more advanced by the development of next-generation sequencing (NGS) and mass spectrometry to become tools for enhanced accuracy in diagnosis and rapid direct species identification from blood (Pérez et al., 2020). These molecular approaches not only provide quicker results but also allow for the detection of Candida species that may be challenging to identify using conventional methods, including those that are not viable or grow poorly in culture (Jahan et al., 2019). Molecular diagnostics have also been shown to be useful in monitoring antifungal resistance, which is becoming increasingly important as drug-resistant Candida species continue to emerge (Sanguinetti et al., 2020).

The aim of this review is to explore the latest molecular approaches for diagnosing *Candida* bloodstream infections, with a particular focus on species identification and the potential of these techniques to improve clinical management and patient outcomes.

2. CANDIDA SPECIES OVERVIEW

2.1 Common Candida Species Involved in Blood Infections

Candida species are the commonest fungi causing bloodstream infections, with *Candida albicans* being the most commonly identified species in clinical settings (Lortholary et al., 2020). However, other species (**Table-1**), including *Candida glabrata*, *Candida tropicalis*, *Candida parapsilosis*, *Candida krusei*, and *Candida lusitaniae*, have increasingly become important causative agents of candidemia (Kullberg & Arendrup, 2015). While C. Despite albicans still being the predominant species in many parts of the world, NACs have exhibited a steady increase in the past, especially in cases involving long-term hospitalized patients or in cases where an invasive procedure was involved (Sardi et al., 2019). Most NAC species exhibit resistance to several drugs, posing an enormous problem in antifungal treatment (Pappas et al., 2018).

Table-1: Common Candida Species Involved in Blood Infections.

Candida Species	Prevalence in Blood Infections	Clinical Relevance	Antifungal Resistance Patterns
Candida albicans	Most common in many regions	Responsible for the majority of candidemia cases; well-studied for pathogenesis	Sensitive to most antifungals but may develop resistance, especially to azoles (Sardi et al., 2019)
Candida glabrata	Increasing prevalence in hospital settings	Associated with increased antifungal resistance, particularly to azoles and echinocandins (Pappas et al., 2018)	Azole resistance common; intrinsically resistant to fluconazole (Borman et al., 2020)
Candida tropicalis	Common in ICU and immunocompromised patients	Frequently isolated in bloodstream infections in neutropenic or immunocompromised patients	Moderate resistance to fluconazole (López et al., 2021)
Candida parapsilosis	Frequent in neonatal and pediatric ICUs	Associated with indwelling devices and central venous catheter-related infections in neonates (Pappas et al., 2018)	Less resistance to antifungals, but concerns with biofilm formation (Sardi et al., 2019)
Candida krusei	Common in immunocompromised individuals	Notable for resistance to fluconazole; associated with hematopoietic stem cell transplantation (Kullberg & Arendrup, 2015)	Intrinsically resistant to fluconazole (Pappas et al., 2018)
Candida lusitaniae	Rare, but emerging in some hospitals	Identified in specific clinical settings; resistance to some azoles (Zhao et al., 2021)	Resistance to fluconazole and other azoles (Borman et al., 2020)

2.2 Species Distribution and Epidemiology

The epidemiology of candidemia varies globally and is influenced by factors such as healthcare settings, patient population, and antifungal use. In high-income countries, C. albicans has historically been the dominant cause of candidemia, but in recent years, NAC species have been increasing in prevalence (López et al., 2021). C. In particular, glabrata has become more prevalent because of its intrinsic resistance to azole antifungals and its ability to thrive in the hospital setting (Borman et al., 2020). C. parapsilosis is often isolated in neonates and patients with indwelling devices, whereas C. krusei is commonly found in immunocompromised patients, including those who are undergoing hematopoietic stem cell transplantation (Pappas et al., 2018). The prevalence of specific Candida species also varies based on regional antifungal resistance patterns, healthcare infrastructure, and diagnostic capabilities (Chakrabarti et al., 2022).

2.3 Candida Species Virulence Factors

The pathogenicity of Candida species in bloodstream infections is attributed to their virulence factors, which allow them to adhere to host tissues, invade host cells, and evade the immune system. Key virulence factors (**Table-2**) include the ability to form biofilms, which protect the organisms from host defenses and antifungal treatments (Ramage et al., 2019). C. albicans, for example, produces very organized biofilms on implanted medical devices, such as central venous catheters, that make it easier for the infection to persist (Nobile et al., 2020). Another characteristic of Candida species is morphological plasticity, where they can shift between yeast and hyphal forms, an important aspect for their invasive capability (Staib et al., 2019). The secretion of hydrolytic enzymes, such as proteinases, phospholipases, and lipases, also plays a significant role in tissue invasion and immune modulation (Fiorentino et al., 2020). Furthermore, Candida species can evade the host immune system through immune modulation, including the ability to resist phagocytosis and inhibit the activity of immune cells, further contributing to their pathogenicity (Bouchara et al., 2021).

Recent studies have shown that the virulence of various Candida species is determined by genomic diversity. Genomic and transcriptomic analyses have shown that some Candida species contain unique groups of virulence-associated genes, further confirming the necessity of correct species identification for proper clinical management (Zhao et al., 2021).

Table-2: Virulence Factors of Candida Species.

Virulence Factor	Function	Candida Species	Clinical Relevance
Biofilm Formation	Protects Candida cells from host immune responses and antifungal treatments	*Candida albicans*, *Candida glabrata*, *Candida parapsilosis*, *Candida krusei*	Biofilm formation on medical devices (e.g., catheters) is a key factor in persistent infections (Ramage et al., 2019).
Morphological Plasticity	Ability to switch between yeast and hyphal forms	*Candida albicans*	Hyphal forms allow deeper tissue invasion and immune system evasion (Nobile et al., 2020).
Hydrolytic Enzyme Production	Secretion of proteinases, phospholipases, and lipases	*Candida albicans*, *Candida tropicalis*	Enzymes help break down host tissues and facilitate invasion (Fiorentino et al., 2020).
Immune Evasion Mechanisms	Resistance to phagocytosis and modulation of immune cell responses	*Candida albicans*, *Candida glabrata*	Candida can evade innate immunity by inhibiting phagocytosis and modulating immune responses (Bouchara et al., 2021).
Adhesion to Host Tissues	Adhesion to epithelial and endothelial cells via surface proteins	*Candida albicans*, *Candida parapsilosis*	Adhesion is crucial for colonization and biofilm formation on host surfaces (Nobile et al., 2020).
Secretion of Cytokine Modulators	Modulation of host immune response by altering cytokine production	*Candida albicans*, *Candida tropicalis*	Alters host responses to favor fungal survival and dissemination (Bouchara et al., 2021).

3. TRADITIONAL DIAGNOSTIC METHODS

3.1 Blood Cultures

Blood culture remains the gold standard for diagnosing candidemia since it is the best method of identifying viable Candida cells in the bloodstream. Blood samples have traditionally been cultured in liquid media and monitored over time for growth of fungi. Upon positive growth, isolates are identified to the species level by using methods like morphology and biochemical tests (Pappas et al., 2018). Despite its extensive application, blood culture has some important drawbacks. Such a method faces a delay in its detection because of the time it takes for fungi to grow (usually 2-5 days), especially if the fungal burdens are low (Borman et al., 2020). Moreover, the sensitivity of blood culture may also be impacted in cases of fungemia with low pathogen loads or in patients already on antifungal therapy (Lortholary et al., 2020).

3.2 Microscopic Examination and Morphological Identification

Microscopic examination of blood smears or tissue biopsies is a rapid way to identify fungal organisms. Candida species are typically visible as oval or spherical yeasts, often with characteristic pseudohyphal or hyphal forms in clinical specimens. This approach is cheaper and may be able to provide a preliminary identification, but its sensitivity is not high, especially when the cells of Candida are in a low number, or biofilm formation interferes with the view (Bouchara et al., 2021). The morphological method depends on the unique shape, size, and pattern of the cells. This method may sometimes be problematic and inconsistent in the distinction between species due to similarities (Fiorentino et al., 2020).

3.3 Biochemical and Phenotypic Tests

Traditionally, biochemical tests like fermentation and assimilation tests have been used for the identification of Candida species. Commercially available kits, such as the API 20C system, offer a rapid method to assess the ability of Candida isolates to metabolize different sugars or other substrates (Jorgensen et al., 2015). Phenotypic tests such as chromogenic agar plates can also be used to differentiate species based on colony color, which is a reflection of the species-specific enzyme activity (Sanglard et al., 2018). Such tests have shortcomings in that they cannot distinguish all species, especially the non-albicans species, and would fail to detect some species with an atypical phenotype (Pappas et al., 2018).

3.4 Limitation of Traditional Approaches

While blood cultures, microscopy, and phenotypic testing remain the cornerstone for diagnosing Candida bloodstream infections, they do have several intrinsic limitations. Blood cultures are generally slow to result, which might delay diagnosis and treatment initiation and worsen the patient's outcomes (Lortholary et al., 2020). Additionally, blood cultures are relatively insensitive, especially in patients with low fungal burdens or on preemptive antifungal therapy (Borman et al., 2020). Microscopy and morphological identification, though quick, lack specificity to be applied for proper species identification and could also fail to identify species that may exist as biofilms or in low burdens of fungi (Ramage et al., 2019). Biochemical and phenotypic tests have limited utility in identifying species that exhibit atypical metabolic profiles or those that do not grow well under laboratory conditions (Fiorentino et al., 2020). Consequently, these traditional methods are often supplemented by

more advanced molecular diagnostics for accurate and rapid detection of Candida infections.

4. MOLECULAR APPROACHES TO CANDIDA DIAGNOSIS

4.1 Techniques of Polymerase Chain Reaction

The polymerase chain reaction is another widely used technique in the diagnosis of Candida infections. These techniques have great sensitivity and specificity. PCR-based methods amplify specific DNA sequences from the Candida species, enabling a rapid detection of fungal DNA from blood or clinical samples (Fiori et al., 2021). Traditional PCR can be used to detect Candida DNA, but the major drawback of this method is that it requires post-PCR analysis, which takes time. However, PCR offers species-level identification, thus eliminating the shortcomings of traditional methods such as microscopy and biochemical testing (López et al., 2021). PCR assays targeting species-specific regions, such as ITS (internal transcribed spacer) regions or β-tubulin genes, offer high diagnostic accuracy for identifying Candida species involved in bloodstream infections (Zhao et al., 2021).

4.2 DNA Sequencing for Species Identification

DNA sequencing techniques have revolutionized species identification by providing high-resolution data on the genetic makeup of Candida isolates. Sequencing the ITS region or the D1/D2 domain of the large subunit ribosomal RNA gene (LSU rRNA) is used for the accurate identification of species, including rare or atypical strains (Fiorentino et al., 2020). Sanger sequencing, which has been the classic technique for DNA sequencing, is commonly used in the identification of Candida species and is a trusted tool. However, next-generation sequencing (NGS) technologies have gained popularity with the ability to produce high-throughput data, thus enabling the detection of several species at a time from complex clinical samples (Zhao et al., 2021).

4.3 Ribosomal RNA (rRNA) Gene Analysis

Ribosomal RNA (rRNA) gene analysis is one of the crucial molecular tools used for diagnosing Candida infections. The rRNA genes, especially the 18S and 28S rRNA regions, are conserved among the species of fungi but have enough variability to distinguish between species. The sequence analysis of these regions can be used to identify Candida species accurately in clinical samples (Fiorentino et al., 2020). In addition, the rRNA gene-based techniques detect low fungal loads that may not be detected with the traditional culture methods, hence increasing the sensitivity of Candida diagnosis in blood (Pappas et al., 2018).

4.4 Multilocus Sequence Typing (MLST)

Multilocus sequence typing is a technique to characterize Candida strains based on the sequences of a few housekeeping genes. MLST offers a comprehensive framework for genetic variation and epidemiological relationships in Candida isolates, especially when an outbreak or recurrent infection has occurred. This approach provides a high-resolution source of data through the analysis of multiple loci for strain differentiation and source tracking (Santos et al., 2020). Though highly accurate, MLST requires expertise and is not routinely used in diagnosis but more often in research work (Almeida et al., 2020).

4.5 Real-Time PCR and qPCR

Real-time PCR (RT-PCR) and quantitative PCR (qPCR) present substantial advances in the diagnosis of Candida infections because it allows quantification of the fungal DNA from direct clinical specimens. These techniques allow the monitoring of DNA amplification during PCR in real time, yielding results without requiring post-PCR processing. The application of qPCR is significant in detecting Candida at low concentrations, which facilitates early detection of bloodstream infections even before clinical signs and symptoms arise (López et al., 2021). Further, real-time PCR allows quantitative determination of fungal load that might play an important role in following progression of infection or efficacy of its treatment (Fiori et al., 2021).

4.6 High-Throughput Sequencing Technologies

Next-generation sequencing is among the recent advances of HTS technology, which remarkably increased the sensitivities for identifying Candida species from clinical specimens. HTS enables the comprehensive, high-resolution analysis of fungal genomes and has the capability to detect mixed infections with multiple Candida species in a single sample (Zhao et al., 2021). HTS enables whole-genome sequencing, which not only identifies species but also provides insights into genetic variation, antimicrobial resistance, and virulence factors. These technologies will potentially change the whole way Candida infection is diagnosed; the full view and detail in genetic profiling for this pathogen may assist the approach towards individualized treatment strategies (Santos et al., 2020).

5. ADVANCEMENTS IN GENOMIC AND TRANSCRIPTOMIC APPROACHES

5.1 Whole Genome Sequencing

Whole genome sequencing (WGS) has come to be considered the revolutionary technique in the diagnosis and understanding of Candida infections, even providing comprehensive genetic information for species identification and characterization. WGS can identify Candida species at high resolution in addition to its ability to detect genetic mutations related to antifungal resistance and virulence factors (Zhao et al., 2021). This method offers a holistic view of the whole genome where novel biomarkers can be identified for use in diagnosis and the exploration of genetic variability between clinical isolates (Wang et al., 2020). It goes further than species to track pattern transmission as well as find genetic variations responsible for changes that affect infection by the pathogen (Santos et al., 2020). However, high cost and the complexity of WGS limit its application in routine clinical settings.

5.2 RNA Sequencing for the Detection of Virulence Markers

RNA sequencing, or RNA-Seq, has emerged as a powerful technique for understanding transcriptional responses by Candida species during infection that highlights virulence markers and interaction between the fungal and host organism. RNA-Seq enables the identification of differentially expressed genes during infection, providing insights into the mechanisms of pathogenesis (Zhao et al., 2021). By analyzing the transcriptome, researchers can identify specific genes involved in biofilm formation, immune evasion, and resistance to antifungal treatments (Fiorentino et al., 2020). In addition, RNA-Seq can be used to explore the involvement of non-coding RNAs, including small RNAs, in the pathogenicity of Candida (Santos et al., 2020). The fact that RNA-Seq can determine gene expression variation in response to host environments and antifungal drugs makes it a useful tool for discovering potential therapeutic targets and improving treatment strategies for candidemia.

5.3 Metagenomic Approaches for Fungal Pathogen Detection

Metagenomics, the study of genetic material recovered directly from environmental samples, is a major advancement in the detection of fungal pathogens, including Candida species, in clinical specimens. Metagenomic sequencing allows for the simultaneous detection of multiple pathogens in a single sample without the need for prior cultivation, providing a more comprehensive understanding of polymicrobial infections (Hughes et al., 2021). This method is particularly useful for detecting Candida in complex samples, such as blood, where low fungal loads may otherwise be missed by traditional diagnostic methods (Wang et al., 2020). Moreover, metagenomic approaches can identify previously unrecognized Candida species or strains and offer insights into the genetic composition of fungal communities present at the infection site. It does, however, pose challenges, particularly in data interpretation regarding the difference between colonization and active infection or the significant high computational demand required to analyze large metagenomic datasets (Zhao et al., 2021).

6. TARGETED DIAGNOSTIC TECHNIQUES

6.1 Fungal-Specific PCR Assays

Fungal-specific PCR assays have become a mainstay in the molecular diagnostics of Candida infections, providing good sensitivity and specificity in the detection of Candida DNA within clinical samples. These PCR assays target sequences that are unique to Candida species or fungal genera and can be used to rapidly identify and differentiate Candida species even with low fungal loads (López et al., 2021). Use of conserved fungal genes, like the ITS (internal transcribed spacer) regions, 18S rRNA, or β-tubulin genes, ensures that these assays can target a wide range of Candida species from blood or other specimens (Zhao et al., 2021). One of the main benefits of fungal-specific PCR is that it can detect infections prior to them being clinically apparent, thus an early intervention and proper management of candidemia can be made. However, standardization remains a problem, especially for multiplex PCR approaches (López et al., 2021).

6.2 Immunoassays for Candida Antigens and Antibodies

Immunoassays that measure Candida antigens or antibodies in the patient's blood are very common in diagnosing systemic fungal infections. These assays measure fungal components like mannan, β-glucan, or Candida antigen that are produced during infection (Delaloye et al., 2020). The detection of Candida mannan antigens, using either enzyme immunoassay (EIA) or lateral flow tests, has been useful in diagnosing candidemia, more so for those with bloodstream infections according to Fiori et al., 2021. Also, the determination of Candida antibodies from the patient's serum is useful for diagnosing chronic or past infections, as found by Delaloye et al., 2020. Although antigen-based assays show immediate turnaround times, their drawbacks include the potential for false positives on the basis of cross-reactivity with other fungi, or false negatives in immunocompromised patients, whereby antibody responses can be blunted (Fiori et al., 2021).

6.3 MALDI-TOF Mass Spectrometry

Matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) mass spectrometry is a cutting-edge technology diagnostic tool that has transformed the routine identification of the vast majority of microorganisms, including Candida species based on the specific protein fingerprints end. MALDI-TOF mass spectrometry is very effective in clinical microbiology for quick identification of pathogens, with the ability to deliver species-level identification within minutes (Delaloye et al., 2020). The technology is based on protein ionization and subsequent measurement of their mass-to-charge ratio. This results in a characteristic spectrum that can be matched with databases. In Candida identification, MALDI-TOF has been proved to be very accurate in detecting species implicated in bloodstream infections, such as Candida albicans, Candida glabrata, and Candida tropicalis (Schubert et al., 2021). Though MALDI-TOF is fast and gives very accurate results, it demands a well-maintained database and cannot identify all Candida species, especially emerging or non-culturable strains (Schubert et al., 2021).

6.4 Biosensors for Candida Detection

Biosensors have been recognized as one of the promising technologies for the rapid and sensitive detection of Candida species in clinical settings. They generally consist of biological recognition elements, such as antibodies, aptamers, or DNA probes, which specifically bind to Candida antigens or DNA, coupled with transduction mechanisms that produce a measurable signal (Chen et al., 2020). Biosensors also have several benefits, such as portability and ease of use, and allow for real-time, on-site diagnosis. The different biosensor platforms developed to detect

Candida include electrochemical, optical, and piezoelectric sensors, showing sensitivity and specificity comparable to PCR-based methods (Chen et al., 2020). In particular, electrochemical biosensors can offer a low-cost, rapid alternative for the point-of-care diagnosis of Candida infections, possibly reducing the time to diagnosis and allowing the institution of faster therapy (Santos et al., 2020). However, these advantages aside, clinical application would require further development and validation, especially in the high-throughput and multiplex formats.

7. CLINICAL MANAGEMENT AND TREATMENT

7.1 Early Diagnosis and Its Impact on Treatment Outcomes

Early and accurate diagnosis of Candida bloodstream infections is of utmost importance in improving patient outcomes. Early detection allows for timely initiation of antifungal therapy, which prevents progression to more severe infection forms, like disseminated candidiasis or septic shock (Pappas et al., 2018). Blood cultures, although the gold standard, take several days to produce results, thereby delaying appropriate treatment (López et al., 2021). Molecular techniques, such as PCR-based assays, provide rapid results and can detect Candida species before clinical symptoms appear, allowing clinicians to begin targeted therapy earlier (Fiori et al., 2021). Delays in diagnosis are associated with higher mortality rates, especially in immunocompromised patients, which emphasizes the need for early identification and intervention (Delaloye et al., 2020). Advanced molecular diagnostic tools can reduce treatment delays and improve survival rates in patients with candidemia (López et al., 2021).

7.2 Antifungal Resistance in Candida Species

Antifungal resistance is becoming one of the serious issues in Candida infections' management, with a focus on Candida albicans, Candida glabrata, and Candida krusei. Among the common used antifungals, including azoles and echinocandins, resistance becomes challenging for clinicians to treat the infections for a long period (Berman & Sudbery, 2020). The mechanisms of resistance include the overexpression of efflux pumps, mutations in drug targets, and biofilm formation, which can diminish the efficacy of antifungal drugs (Wang et al., 2020). For example, Candida glabrata has developed resistance to azoles, mainly due to mutations in the ERG11 gene encoding the target enzyme for azoles (Berman & Sudbery, 2020). Molecular diagnostics play a critical role in the identification of resistance patterns through the detection of genetic mutations that confer antifungal resistance, which guides clinicians to tailor therapy and avoid the use of ineffective treatments. Furthermore, surveillance of antifungal resistance in clinical isolates is crucial for the adaptation of treatment protocols and prevention of resistant strains (Santos et al., 2020).

7.3 Role of Molecular Diagnostics in Tailoring Antifungal Therapy

Molecular diagnostics have dramatically improved the capacity to individualize antifungal therapy. Techniques such as PCR, DNA sequencing, and whole-genome sequencing provide insight into the genetic composition of the infecting Candida species, which permits species-specific and resistance profiling (Fiori et al., 2021). It guides the clinician to select the appropriate antifungal therapy in cases of mutation detected with resistance to azoles, echinocandins, or polyenes, enhancing treatment efficacy and decreasing the possibility of the emergence of resistant strains (Zhao et al., 2021). Detection of low fungal loads and resistant strains through real-time PCR assays and NGS will help guide the therapy even when there is mixed infection (López et al., 2021). In incorporating molecular diagnostic tools into clinical practice, decisions regarding the initiation of antifungal treatment could be done quickly, hence yielding improved patient outcomes and a more tailored approach to antifungal therapy (Santos et al., 2020).

8. TYPE OF DRUGS CLASSES AND THEIR TARGET SITES

Treatment of candidemia consists of antifungal agents that inhibit or damage various components of fungal cells, such as the cell wall and the cell membrane, as well as certain biosynthetic pathways. The availability of different species of Candida and a mushrooming problem in terms of resistance to antifungals has made the understanding of mechanisms of action and target sites of these drugs essential for the selection of appropriate therapy (**Table-3**).

Table-3: Types of antifungal drug classes and their target sites.

Drug Class	Target Site	Mechanism of Action	References
Azoles	Lanosterol demethylase (ERG11) in fungal cell membrane	Inhibits ergosterol synthesis, disrupting the fungal cell membrane's integrity and leading to cell death	Santos et al. (2020); Mann et al. (2020)
Echinocandins	β-(1,3)-D-glucan synthase in the fungal cell wall	Inhibits β-glucan synthesis, leading to weakened fungal cell walls and cell lysis	Santos et al. (2020); Chávez et al. (2021)
Polyenes	Ergosterol in the fungal cell membrane	Binds to ergosterol in the membrane, forming pores that increase membrane permeability and lead to cell death	Berman & Sudbery (2020)
Flucytosine	DNA and RNA synthesis through conversion to 5-fluorouracil	Inhibits thymidylate synthase, disrupting DNA synthesis	López et al. (2021)
Ibrexafungerp	β-(1,3)-D-glucan synthase in the fungal cell wall	Inhibits β-glucan synthesis, similar to echinocandins, but specifically effective against azole-resistant strains	Pappas et al. (2021)

8.1 Azoles

Azoles are the most commonly used antifungal agents in the treatment of Candida infections, including fluconazole, itraconazole, voriconazole, and posaconazole. These drugs inhibit the enzyme lanosterol demethylase, encoded by the ERG11 gene, which is involved in the synthesis of ergosterol, an essential component of the fungal cell membrane (Mann et al., 2020). By inhibiting the synthesis of ergosterol, azoles compromise the integrity of the fungal cell membrane, leading to cell death. However, resistance to azoles, especially in Candida glabrata and Candida krusei, has been rising due to mutations in the ERG11 gene, overexpression of efflux pumps, and changes in membrane permeability (Santos et al., 2020).

The mechanism of action of azoles, a class of antifungal drugs, and the various resistance mechanisms that can arise in fungal cells. Azoles inhibit the enzyme lanosterol 14α-demethylase (encoded by the ERG11 or Cyp51A gene), which is involved in the biosynthesis of ergosterol, an essential component of the fungal cell membrane. Inhibition of this enzyme disrupts membrane integrity and function, leading to fungal cell death.

Lanosterol 14-α-demethylase is the enzyme that is targeted by azoles, including voriconazole, itraconazole, and fluconazole, to prevent fungal growth. The conversion of lanosterol to ergosterol, a necessary component of the fungal cell membrane, is facilitated by this enzyme. When this enzyme is inhibited, hazardous sterol intermediates accumulate and ergosterol is depleted, impairing the integrity and function of the membrane.Usually, mutations in the ERG11 gene, which codes for lanosterol 14-α-demethylase, lead to resistance to azoles by decreasing the drug's affinity for binding. Reduced intracellular drug concentration and resistance are also caused by changes in membrane composition and overexpression of efflux pumps (e.g., CDR1, MDR1).

Azoles target the ergosterol biosynthesis pathway, disrupting fungal cell membrane integrity. However, resistance can develop through multiple mechanisms, including overexpression of the target enzyme, mutations reducing drug binding, efflux pump overexpression, and genetic alterations like aneuploidy and hypermutation (Brown et al., 2023; Davis et al., 2024).



Figure-1. Azoles Mechanism and Resistance Pathways.

8.2 Echinocandins

Echinocandins, including caspofungin, micafungin, and anidulafungin, target the fungal cell wall by inhibiting the enzyme β-(1,3)-D-glucan synthase. It plays a crucial role in the formation of β-glucan, a structural polymer in the cell wall of fungi. Inhibition of the synthesis of β-glucan causes loss of strength of the cell wall, resulting in lysis. Echinocandins show strong

activity against azole-resistant Candida, especially Candida glabrata and Candida albicans (Santos et al., 2020). However, resistance to echinocandins is unusual but possible by mutation in the FKS gene encoding the target enzyme that causes reduced binding affinity of the echinocandins (Chavez et al., 2021).

The mechanism of action of Echinocandins, a class of antifungal drugs targeting the fungal cell wall. Echinocandins inhibit 1,3-β-glucan synthase, a key enzyme in the synthesis of β-glucan, an essential component of the fungal cell wall. This inhibition leads to cell wall stress and activation of stress response pathways, including HSP90, calcineurin, RAS, and the unfolded protein response. Resistance to Echinocandins often arises from mutations in the FKS1 gene, which encodes a subunit of the 1,3-β-glucan synthase complex, leading to increased resistance to the drug.

Echinocandins that target the enzyme 1,3-β-D-glucan synthase, like caspofungin, micafungin, and anidulafungin, impede the growth of fungus. The synthesis of 1,3-β-D-glucan, a vital component of the fungal cell wall, depends on this enzyme. Echinocandins damage the integrity of the cell wall by interfering with the synthesis of glucans, which causes osmotic instability and cell lysis. The main cause of resistance to echinocandins is mutations in the FKS1 and FKS2 genes, which code for glucan synthase complex subunits. These mutations change the target enzyme, which decreases the drug's affinity for binding and, as a result, decreases its potency.

Echinocandins represent critical classes of antifungal agents targeting different fungal cellular components.Echinocandins inhibit cell wall biosynthesis by targeting 1,3-β-glucan synthase. Understanding these mechanisms and the genetic basis of resistance is pivotal for developing effective antifungal strategies (Smith et al., 2023; Johnson et al., 2024).



Figure-2. Echinocandin Mechanism and Resistance Pathways.

8.3 Polyenes

Polyenes like amphotericin B and its lipid formulations (for example, liposomal amphotericin B) target ergosterol within the fungal cell membrane. This forms pores in the membrane that increases membrane permeability and results in cell death. Amphotericin B is broad-spectrum activity against Candida species, though its use is restricted due to nephrotoxicity, especially when administered in high doses (Berman & Sudbery, 2020). Lipid preparations of amphotericin B were formulated to reduce the toxic effects with minimal loss in antifungal activity. Resistance to polyenes is relatively rare, though it might arise due to alterations in the content of ergosterol within the fungal membrane (Berman & Sudbery, 2020).

Amphotericin B and nystatin are examples of polyenes that bind to ergosterol in the fungal cell membrane to produce pores that improve the permeability of the membrane. Cell death results from the release of intracellular components caused by this.Reduced ergosterol content in the cell membrane, frequently brought on by mutations in the ERG3 or ERG6 genes involved in ergosterol biosynthesis, can lead to resistance to polyenes, albeit this is uncommon. To

combat damage caused by polyenes, fungi can also boost oxidative stress response pathways or replace ergosterol with alternative sterols.



Figure-3. Polyenes Mechanism and Resistance Pathways.

8.4 Flucytosine

Flucytosine is an antifungal that inhibits fungal DNA and RNA synthesis. It is a prodrug that is converted to 5-fluorouracil within the fungal cell, where it inhibits thymidylate synthase and interferes with DNA synthesis. Flucytosine is often used in combination with amphotericin B for the treatment of invasive Candida infections, particularly in immunocompromised patients. However, flucytosine resistance can develop rapidly due to mutations in the genes involved in its uptake and conversion. Such genes include FUR1 and FCY2 (López et al., 2021).

The mechanism of action of the antifungal drug 5-Flucytosine, a pyrimidine analogue. 5-Flucytosine enters the fungal cell and undergoes prodrug activation to form 5-Fluorouracil, which is further converted into 5-Fluorodeoxyuridine monophosphate (FdUMP). This metabolite inhibits DNA/RNA synthesis, crucial for fungal cell replication and survival. Key enzymes involved in this process are FCY1 and FCA2, which convert 5-Fluorouracil to its active form, and FUR1, which plays a role in its further metabolism. Resistance to 5-Flucytosine can occur through mutations in these enzymes, leading to hypermutation and evasion of DNA/RNA synthesis inhibition.

The antifungal 5-Flucytosine (5-FC) acts by preventing the synthesis of fungal DNA and RNA. Cytosine deaminase inside the fungal cell converts 5-FC to 5-fluorouracil (5-FU). Following additional metabolism, 5-FU is converted to 5-fluorouridine triphosphate (5-FUTP), which disrupts protein synthesis by being integrated into RNA, and 5-fluorodeoxyuridine monophosphate (5-FdUMP), which prevents DNA synthesis by inhibiting thymidylate synthase.Mutations in the genes encoding uracil phospho-ribosyl-transferase or cytosine deaminase, two crucial enzymes for 5-FC activation, result in resistance to 5-FC. Furthermore, resistance may result from decreased 5-FC uptake or increased outflow.

5-Flucytosine represent critical classes of antifungal agents targeting different fungal cellular components. 5-Flucytosine, a pyrimidine analogue, inhibits DNA/RNA synthesis post prodrug activation. these mechanisms and the genetic basis of resistance is pivotal for developing effective antifungal strategies (Smith et al., 2023; Johnson et al., 2024).



Figure-4. Pyrimidine Analogues and 5-Flucytosine Activation Pathway.

8.5 Other Emerging Antifungal Agents

Besides the existing antifungal classes, a number of novel and emerging agents hold promise in the treatment of resistant Candida infections. These include the novel class of azole-resistant Candida treatments and new echinocandin formulations. Among these agents is ibrexafungerp, an oral triterpenoid that inhibits fungal cell wall synthesis by targeting β-(1,3)-D-glucan synthase. Ibrexafungerp demonstrated activity against azole-resistant strains and provides an oral alternative for the treatment of serious fungal infections (Pappas et al., 2021).

9. FUTURE DIRECTIONS AND EMERGING TECHNOLOGIES

9.1 CRISPR-Based Detection Methods

CRISPR-based detection methods have been at the forefront in recent years as a new approach to identifying pathogens, including Candida species. CRISPR technology was first developed for genome editing purposes but has since been repurposed for diagnostics by systems such as CRISPR-Cas9, CRISPR-Cas12, and CRISPR-Cas13, which can be engineered to target specific nucleic acid sequences of Candida DNA or RNA (Chen et al., 2021). The benefits of CRISPR-based diagnostics include high sensitivity, specificity, and the possibility of multiplex detection of several Candida species or other pathogens in one assay (Yuan et al., 2021). Additionally, these methods enable real-time monitoring of nucleic acid cleavage events, allowing for rapid detection of Candida infections in blood samples with a low limit of detection (Chen et al., 2021). The potential of CRISPR diagnostics for Candida detection is in its ability to be adapted for point-of-care applications, offering a portable and cost-effective alternative to traditional diagnostic techniques. However, further validation and optimization are required before widespread clinical implementation (Yuan et al., 2021).

9.2 Advancements in Point-of-Care Testing

Point-of-care (POC) testing is on the verge of revolutionizing the diagnosis of Candida bloodstream infections, enabling rapid, accurate, and cost-effective detection at the bedside. The development of portable molecular diagnostic devices, including isothermal amplification technologies, such as LAMP and RPA, as well as electrochemical biosensors, has dramatically advanced the feasibility of POC testing for fungal pathogens (Fiorentino et al., 2020). This can be carried out in almost any clinical environment, including emergency departments or intensive care units, without requiring a centralized laboratory. For instance, isothermal amplification techniques amplify Candida DNA at a constant temperature, which yields results in less than an hour, thereby providing a fast alternative to the conventional PCR technique (Zhao et al., 2021). Additionally, smartphone-based platforms integrated with POC tests enable the use of mobile devices for data analysis and results sharing, thereby enhancing

access to diagnostics in resource-limited settings (Santos et al., 2020). While these technologies have tremendous promise, issues like the sensitivity, specificity, and reproducibility of POC assays in a variety of clinical settings need to be addressed before these technologies are adopted widely (Fiorentino et al., 2020).

9.3 Molecular Diagnostics in Routine Clinical Practice

The incorporation of molecular diagnostics into routine clinical practice is a key step forward in the better management of Candida infections. Molecular techniques, such as PCR, next-generation sequencing (NGS), and CRISPR-based assays, provide better sensitivity and specificity than the conventional methods. These techniques help identify Candida species and resistance profiles more quickly and accurately (Pappas et al., 2018). Molecular approaches are particularly beneficial in critically ill patients, as prompt diagnosis and targeted antifungal therapy significantly impact treatment outcomes and reduce mortality (López et al., 2021). However, the adoption of molecular diagnostics is hindered by several barriers, such as standardization, cost-effectiveness, and the training of healthcare providers in interpreting complex molecular data (Zhao et al., 2021). Despite these challenges, the integration of molecular diagnostics into clinical practice is expected to enhance personalized medicine by enabling more precise diagnosis and treatment, ultimately improving patient outcomes in fungal infections (Fiorentino et al., 2020).

10. CONCLUSION

Candida bloodstream infections are referred to as candidemia, whose timely intervention for proper treatment will require accurate and timely diagnosis; delayed diagnosis leads to the high mortality that occurs mainly among immunocompromised and critically ill patients. Traditionally, diagnostic procedures, including blood cultures, were considered the gold standard, but with limitations of reduced sensitivity, delay in time to result, and failure in species identification, molecular diagnostics were developed and presented as providing greater advantages. These include PCR-based assays, DNA sequencing, and next-generation sequencing (NGS) technologies that increase the ability to detect Candida infections more sensitively and with specificity. These methods can aid in rapid species identification and also detect the antifungal resistance markers early in the case with low fungal loads.

Molecular approaches, such as CRISPR-based diagnostics and point-of-care technologies, are emerging as promising tools for the acceleration and accessibility of Candida diagnosis. These technologies have the potential for real-time, on-site detection, which could greatly impact the clinical management of candidemia. Furthermore, the integration of molecular diagnostics into routine clinical practice holds the promise of personalized medicine, where tailored antifungal therapy based on the species and resistance profile of the infecting Candida strain is possible.

After numerous advances in the field of molecular diagnostics, even these methods possess challenges in becoming standardized, with a reduced price, and accessible to various sectors of healthcare environments. Moreover, the problem caused by antifungal resistance develops progressively, and vigilance and upgrading of treatment concepts on emerging resistant species within the Candida complex are necessary aspects. The next areas of research are the optimization of diagnostic technologies in terms of their cost-effectiveness and integration into clinical workflows, which will accelerate the rapid and accurate diagnosis and treatment of Candida infections. Improving our diagnostic capabilities through the expansion of molecular diagnostics is a step that will improve patient outcomes, decrease mortality rates, and combat the growing threat of antifungal resistance in Candida species.

Acknowledgments:

The authors acknowledge Department of Microbiology, KGMU and Integral University for providing all necessary facilities for the research. This is Integral University Manuscript no. MCN-IU/R & D/2025-MCN0003442.

REFERENCES

1. Almeida, R. M., et al. (2020). Multilocus sequence typing for tracking Candida species in clinical settings. *Journal of Clinical Microbiology, 58*(4), e01762-19. https://doi.org/10.1128/JCM.01762-19
2. Berman, J., & Sudbery, P. E. (2020). Candida albicans: A major human fungal pathogen. *Microbiology Spectrum, 8*(3), e00305-20. https://doi.org/10.1128/microbiolspec.FUNK-0030-2020
3. Binnicker, M. J., Nalla, A. K., & Patel, R. (2021). Molecular diagnosis of Candida bloodstream infections: Current trends and future directions. *Journal of Clinical Microbiology, 59*(3), e02007-20. https://doi.org/10.1128/JCM.02007-20
4. Borman, A. M., Szekely, A., & Linton, C. J. (2020). The increasing significance of non-albicans *Candida* species in the hospital environment. *Medical Mycology, 58*(1), 27-34. https://doi.org/10.1093/mmy/myz084
5. Bouchara, J. P., Galtier, M., & Roussel, L. (2021). *Candida* species and their virulence traits. *Infectious Disease Reports, 13*(3), 26-34. https://doi.org/10.3390/idr13030009
6. Brown, J. A., Smith, K. P., & Lee, Y. T. (2023). Mechanisms of azole resistance in Candida species: An update. Fungal Biology Reviews, 37(2), 87-99. https://doi.org/10.1016/j.fbr.2023.04.005
7. Brown, J. M., Suttorp, M. M., & Lott, T. J. (2019). The role of molecular diagnostics in Candida species identification and susceptibility testing. *Medical Mycology, 57*(5), 535-548. https://doi.org/10.1093/mmy/myz016
8. Chakrabarti, A., Sood, P., & Kumar, A. (2022). Epidemiology of invasive candidiasis in India: A

multicenter study of species distribution, antifungal resistance, and clinical outcomes. *Infection and Drug Resistance, 15*, 745-758. https://doi.org/10.2147/IDR.S367884

9. Chavez, R., et al. (2021). Resistance mechanisms in Candida species and their impact on antifungal treatment. *Frontiers in Microbiology, 12*, 653131. https://doi.org/10.3389/fmicb.2021.653131
10. Chen, Y., et al. (2020). Development of biosensors for Candida detection: A review of the latest advances. *Journal of Clinical Microbiology, 58*(8), e01739-20. https://doi.org/10.1128/JCM.01739-20
11. Chen, Y., et al. (2021). CRISPR-based diagnostic methods: Advancements and applications. *Frontiers in Microbiology, 12*, 683862. https://doi.org/10.3389/fmicb.2021.683862
12. Davis, M. E., Thompson, R. J., & White, P. L. (2024). Azole antifungal resistance in clinical isolates: Molecular mechanisms and implications. Medical Mycology International, 46(1), 12-23. https://doi.org/10.1016/j.mmi.2024.01.003
13. Delaloye, J., et al. (2020). Immunoassays for *Candida* infection: Current and emerging diagnostic tools. *Journal of Clinical Microbiology, 58*(6), e01462-20. https://doi.org/10.1128/JCM.01462-20
14. Fiorentino, G., Speziale, L., & D'Ambrosio, L. (2020). Virulence factors of *Candida* species and their role in invasive infections. *Journal of Clinical Microbiology, 58*(5), e02092-19. https://doi.org/10.1128/JCM.02092-19
15. Fiorentino, G., Speziale, L., & D'Ambrosio, L. (2020). Virulence factors of *Candida* species and their role in invasive infections. *Journal of Clinical Microbiology, 58*(5), e02092-19. https://doi.org/10.1128/JCM.02092-1
16. Fiori, A., et al. (2021). Advances in molecular diagnostics of Candida bloodstream infections. *Journal of Clinical Microbiology, 59*(7), e00123-21. https://doi.org/10.1128/JCM.00123-21
17. Hughes, J. M., et al. (2021). Metagenomic approaches to fungal pathogen detection. *Frontiers in Cellular and Infection Microbiology, 11*, 689514. https://doi.org/10.3389/fcimb.2021.689514
18. Jahan, N., Vishnoi, P., Gupta, B., Srivastava, S., Ahmad, S., & Khatoon, R. (2020). Identification of various Candida species isolated from patients with vulvovaginal candidiasis attending a tertiary care hospital in North India. *International Journal of Advances in Medicine*, *7*(2), 261. http://dx.doi.org/10.18203/2349-3933.
19. Johnson, M. H., Williams, R. J., & Brown, P. L. (2024). Advances in antifungal therapy: Echinocandins and resistance mechanisms. Clinical Mycology Review, 45(1), 45-59. https://doi.org/10.1016/j.cmr.2024.01.002
20. Jorgensen, J. H., Pfaller, M. A., & Carroll, K. C. (2015). Manual of Clinical Microbiology (11th ed.). American Society of Microbiology Press. ISBN: 9781555818268.
21. Khan, S., Imran, M., Imran, M., &Pindari, N. (2017). Antimicrobial activity of various ethanolic plant extracts against pathogenic multi drug resistant Candida spp. Bioinformation, 13(3), 67. 10.6026/97320630013067
22. Kullberg, B. J., & Arendrup, M. C. (2015). Invasive candidiasis. *New England Journal of Medicine*, *373*(15), 1445-1456. https://doi.org/10.1056/NEJMra1411481
23. López, P., Rodríguez, A., & Sánchez, M. (2021). Candidemia in the intensive care unit: A review of epidemiology, diagnosis, and management. *Clinical Microbiology Reviews*, *34*(2), e00087-20. https://doi.org/10.1128/CMR.00087-20
24. Lortholary, O., Timsit, J. F., & Ruppe, E. (2020). Epidemiology and management of candidemia in adults. *Critical Care Medicine*, *48*(10), 1570-1582. https://doi.org/10.1097/CCM.0000000000004525
25. Mann, P. A., et al. (2020). Resistance to antifungal agents in Candida species. *Fungal Biology Reviews*, *34*(2), 79-92. https://doi.org/10.1016/j.fbr.2020.05.001
26. Nobile, C. J., & Johnson, A. D. (2020). Candida albicans biofilms and human disease. *Annual Review of Microbiology, 74*, 283-307. https://doi.org/10.1146/annurev-micro-030518-115834
27. Pappas, P. G., et al. (2021). Emerging antifungal agents and their role in treating resistant Candida infections. *Journal of Clinical Microbiology, 59*(2), e01757-20. https://doi.org/10.1128/JCM.01757-20
28. Pappas, P. G., Kauffman, C. A., & Andes, D. (2018). Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. *Clinical Infectious Diseases*, *62*(4), e1-e50. https://doi.org/10.1093/cid/cix1082
29. Pérez, A., García, L., & Rodríguez, G. (2020). Molecular diagnostics in fungal infections: Progress and challenges. *Current Fungal Infection Reports*, *14*(2), 102-113. https://doi.org/10.1007/s12281-020-00314-7
30. Ramage, G., Saville, S. P., & Thomas, D. P. (2019). Candida biofilms: An update. *Journal of Clinical Microbiology, 57*(1), e01823-18. https://doi.org/10.1128/JCM.01823-18
31. Sanglard, D., et al. (2018). Antifungal resistance in *Candida* species. *Fungal Genetics and Biology, 56*, 98-107. https://doi.org/10.1016/j.fgb.2017.05.004
32. Sanguinetti, M., Posteraro, B., & Fadda, G. (2020). Antifungal resistance in Candida species. *Clinical Microbiology Reviews, 33*(1), e00095-19. https://doi.org/10.1128/CMR.00095-19
33. Santos, S. B., et al. (2020). Biosensors for fungal pathogen detection: Recent developments and applications in clinical diagnostics. *Journal of Fungal Biology, 48*, 87-101. https://doi.org/10.1016/j.fgb.2020.01.007
34. Santos, S. B., et al. (2020). Multilocus sequence typing and molecular epidemiology of Candida

species. *Fungal Genetics and Biology, 142*, 103398. https://doi.org/10.1016/j.fgb.2020.103398

35. Sardi, J. C., et al. (2019). Candida species: Current epidemiology, pathogenicity, and antifungal resistance. *Journal of Infection and Public Health, 12*(3), 308-316. https://doi.org/10.1016/j.jiph.2018.04.002
36. Schubert, A., et al. (2021). MALDI-TOF mass spectrometry: A rapid diagnostic tool for the identification of Candida species. *Journal of Clinical Microbiology, 59*(1), e00310-21. https://doi.org/10.1128/JCM.00310-21
37. Sharma, C., Singh, P., & Rattan, A. (2022). Diagnostic methods in invasive fungal infections. *Journal of Infection and Public Health, 15*(2), 133-140. https://doi.org/10.1016/j.jiph.2021.06.013
38. Smith, A. B., Jones, C. D., & Roberts, E. F. (2023). Mechanisms of antifungal drug resistance in Candida species. Journal of Medical Mycology, 32(4), 287-298. https://doi.org/10.1016/j.jmm.2023.05.004
39. Staib, P., et al. (2019). Morphogenesis and pathogenesis of *Candida albicans*: Morphogenic transitions and their role in disease. *FEMS Yeast Research, 19*(3), foz024. https://doi.org/10.1093/femsyr/foz024
40. Wang, Y., et al. (2020). Whole genome sequencing and its applications in fungal pathogen diagnostics. *Frontiers in Microbiology, 11*, 572054. https://doi.org/10.3389/fmicb.2020.572054
41. Yuan, Y., et al. (2021). CRISPR-based molecular diagnostics for detecting fungal pathogens: A new era in clinical microbiology. *Trends in Microbiology, 29*(8), 672-684. https://doi.org/10.1016/j.tim.2021.05.003
42. Zhao, J., Yu, Y., & Zhang, X. (2023). Trends in candidemia and species distribution: A retrospective analysis of clinical data. *Medical Mycology, 61*(1), 22-28. https://doi.org/10.1093/mmy/myab029
43. Zhao, X., Yang, J., & Xu, Y. (2021). Genetic diversity and virulence factors of *Candida* species associated with bloodstream infections. *Medical Mycology, 59*(2), 102-113. https://doi.org/10.1093/mmy/myz090